Welcome to our dedicated page for Inflarx news (Ticker: IFRX), a resource for investors and traders seeking the latest updates and insights on Inflarx stock.
InflaRx NV (IFRX) is a clinical-stage biopharmaceutical company pioneering targeted therapies for inflammatory and autoimmune diseases through its proprietary C5a inhibition technology. This page provides investors and healthcare professionals with a comprehensive repository of official updates, including clinical trial progress, regulatory developments, and strategic partnerships.
Access real-time updates on ifx-1 and ifx-2, the company's lead monoclonal antibody candidates, alongside analysis of their potential impact on conditions like hidradenitis suppurativa and ANCA-associated vasculitis. Our curated news feed ensures you stay informed about milestones in drug development without promotional bias.
Key coverage areas include phase trial results, FDA/EMA regulatory communications, patent filings, and collaborative research initiatives. All content is vetted for accuracy and relevance to support data-driven decision-making.
Bookmark this page for streamlined access to InflaRx's latest advancements in complement system modulation. Check regularly for authoritative updates directly impacting the biopharmaceutical investment landscape.
InflaRx (NASDAQ:IFRX), a biopharmaceutical company focused on anti-inflammatory therapeutics, has announced its participation in two major investor conferences in September 2025. The company will present at the Cantor Global Healthcare Conference (September 3-5) with a fireside chat on September 4th at 9:10 AM ET, and at the H.C. Wainwright 27th Annual Global Investment Conference (September 8-10) with a presentation on September 9th at 3:30 PM ET.
InflaRx specializes in developing inhibitors of the complement activation factor C5a and its receptor. Their lead product, vilobelimab, is an intravenous anti-C5a monoclonal antibody, and they are also developing INF904, an oral small molecule C5a receptor inhibitor.
InflaRx (NASDAQ:IFRX) reported Q2 2025 financial results and provided key updates on its pipeline. The company's cash position stands at €53.7 million, with runway extending into 2027. Key developments include anticipated INF904 Phase 2a data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by early November 2025.
Financial highlights show a net loss of €23.0 million (€0.35 per share) for H1 2025. The company's partner Staidson BioPharmaceuticals reported favorable Phase 1/2 results for BDB-001 in ANCA-associated vasculitis, planning to advance to Phase 3. The previously announced Phase 3 pyoderma gangrenosum trial was stopped due to futility, with full data analysis expected later this year.
Additionally, enrollment began in the BARDA-funded JUST BREATHE Phase 2 platform trial investigating vilobelimab for acute respiratory distress syndrome (ARDS). The company maintains EU approval for GOHIBIC (vilobelimab) in SARS-CoV-2-induced ARDS and is pursuing commercial partnerships.
InflaRx (NASDAQ: IFRX), a biopharmaceutical company focused on anti-inflammatory therapeutics, has scheduled its second quarter 2025 financial results announcement for August 7, 2025, before market opening. No earnings call is planned.
The company specializes in developing therapeutics targeting the complement system, particularly the C5a inflammatory mediator. Their key developments include vilobelimab, an intravenous anti-C5a monoclonal antibody, and INF904, an oral small molecule C5a receptor inhibitor. InflaRx maintains operations in Jena and Munich, Germany, and Ann Arbor, Michigan, USA.
InflaRx (NASDAQ: IFRX), a biopharmaceutical company focused on anti-inflammatory therapeutics, has received a Nasdaq deficiency notice on July 11, 2025, for failing to maintain the minimum bid price requirement of $1.00 per share for the last 30 consecutive business days.
The company has been granted an initial 180-day period until January 7, 2026, to regain compliance. If unsuccessful, InflaRx may consider transferring from Nasdaq Global Select Market to Nasdaq Capital Market, which could provide an additional 180 days until July 6, 2026, subject to meeting other listing requirements.
InflaRx develops anti-C5a and anti-C5a receptor technologies, including vilobelimab, an intravenous antibody, and INF904, an oral small molecule inhibitor.
InflaRx, a pioneering biopharmaceutical company listed on Nasdaq (IFRX), has announced it will release its first quarter 2025 financial and operating results on May 7, 2025, before market opening. No earnings call is scheduled.
The company specializes in developing anti-inflammatory therapeutics by targeting the complement system, specifically the C5a and C5aR pathways. Their flagship product, vilobelimab, is an intravenous first-in-class anti-C5a antibody that has shown promising clinical results across multiple indications. Additionally, they are developing INF904, an oral C5a receptor inhibitor.
Founded in 2007, InflaRx maintains offices in Jena and Munich, Germany, and Ann Arbor, Michigan, USA. The company operates through two wholly owned subsidiaries: InflaRx GmbH in Germany and InflaRx Pharmaceuticals in the USA.
InflaRx (IFRX) reported key achievements for 2024 and milestones for 2025. The company received European Commission approval for GOHIBIC® (vilobelimab) to treat SARS-CoV-2-induced ARDS. They reached a 30-patient recruitment milestone in Phase 3 vilobelimab trial for pyoderma gangrenosum, with interim analysis expected by May 2025.
Financial highlights include:
- Cash position of €55.2 million as of December 31, 2024
- Additional €28.7 million raised through public offering in February 2025
- Cash runway extended into 2027
- Net loss of €46.1 million (€0.78 per share) in 2024
- R&D expenses decreased to €35.4 million
The company dosed first patient in Phase 2a trial for oral C5aR inhibitor INF904, with topline data in chronic spontaneous urticaria and hidradenitis suppurativa expected in summer 2025. Multiple data presentations at AAD 2025 highlighted vilobelimab's potential in reducing systemic inflammation.
InflaRx (NASDAQ: IFRX) presented multiple data sets for vilobelimab at the 2025 AAD Annual Meeting, showcasing its potential in treating inflammatory conditions. The presentations included results from studies in pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS).
Key findings for PG showed vilobelimab was well-tolerated with mostly mild to moderate adverse events. The PK/PD data demonstrated approximately 90% reduction in C5a levels by Day 15, sustained through Day 99 in higher dose groups.
In HS, the Phase 2b SHINE trial revealed significant improvements:
- 63.2% reduction in draining tunnels versus 18.0% for placebo
- 40.9% complete resolution of draining tunnels versus 13.0% for placebo (3.1x improvement)
- 800mg vilobelimab significantly reduced C5a concentrations from Day 1
- Safety analysis showed the drug was well-tolerated across all doses
FAQ
What is the current stock price of Inflarx (IFRX)?
What is the market cap of Inflarx (IFRX)?
